AstraZeneca To Pay $11M To Settle Toprol-XL Antitrust Claims

Law360, New York (September 25, 2012, 11:18 PM EDT) -- AstraZeneca Pharmaceuticals LP on Tuesday agreed to pay $11 million to settle claims by a proposed class of indirect purchasers of hypertension drug Toprol-XL that the drugmaker used sham patent litigation to prolong a monopoly on the drug by delaying generic versions.

In a settlement motion filed in Delaware federal court, the plaintiffs sought approval for a settlement class of indirect purchasers of Toprox-XL dating back to May 2005. According to the motion, AstraZeneca denied any wrongdoing but said it wanted to avoid expensive litigation....
To view the full article, register now.